GZ/SAR402671: Ph II MOVES-PD started

Sanofi’s Genzyme Corp. unit began the double-blind, placebo-controlled, dose-escalation, international Phase II MOVES-PD trial to evaluate once-daily oral GZ/SAR402671 in about 231 patients heterozyg...